Lin KJ, Hernández-Díaz S, García Rodríguez LA. Gastroenterology 2011;141:71–9.
The present study investigated the protective effect of proton pump inhibitors (PPIs) and histamine-2-receptor antagonists (H2RAs) in terms of upper gastrointestinal bleeding (UGIB) in the general population as well as in patients taking antithrombotic agents or nonsteroidal anti-inflammatory drugs. In a population-based, nested, case–control study, the authors found that PPI use was associated with a lower risk of UGIB in the general population and in patients on antithrombotic or anti-inflammatory therapy compared with non-use of PPIs. The reduction in risk of UGIB was smaller in H2RA than in PPI users. No dose effect was observed; however, long-term use of gastroprotection was associated with a more pronounced inverse association with UGIB compared with short-term use.
Although published data indicate that proton pump inhibitors (PPIs) can reduce the risk of upper gastrointestinal bleeding (UGIB) in patients who are taking antiplatelet drugs and nonsteroidal anti-inflammatory drugs (NSAIDs), large-scale studies regarding this association are lacking. Therefore, in the present study, the authors investigated the effect of different prevention strategies against UGIB in the general population and in patients on antithrombotic or anti-inflammatory treatments.